Leukemia Research Reports (Jan 2023)
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum
- Aya Nakaya,
- Hirohiko Shibayama,
- Nobuhiko Uoshima,
- Ryosuke Yamamura,
- Satoshi Yoshioka,
- Kazunori Imada,
- Yuji Shimura,
- Masaaki Hotta,
- Toshimitsu Matsui,
- Satoru Kosugi,
- Hitoshi Hanamoto,
- Hitoji Uchiyama,
- Satoshi Yoshihara,
- Shin-ichi Fuchida,
- Yoshiyuki Onda,
- Yasuhiro Tanaka,
- Kensuke Ohta,
- Mitsuhiro Matsuda,
- Junya Kanda,
- Adachi Yoko,
- Miki Kiyota,
- Eri Kawata,
- Ryoichi Takahashi,
- Kentaro Fukushima,
- Hirokazu Tanaka,
- Hideo Yagi,
- Teruhito Takakuwa,
- Naoki Hosen,
- Tomoki Ito,
- Chihiro Shimazaki,
- Akifumi Takaori-Kondo,
- Junya Kuroda,
- Itaru Matsumura,
- Masayuki Hino
Affiliations
- Aya Nakaya
- Department of Hematology, National Hospital Organization Osaka National Hospital, Japan; Kansai Myeloma Forum, Japan; Corresponding author at: Department of Hematology, National Hospital Organization Osaka National Hospital, 2-1-14 Hoenzaka Chuo-ku, Osaka city, Osaka 540-0006, Japan.
- Hirohiko Shibayama
- Department of Hematology, National Hospital Organization Osaka National Hospital, Japan; Kansai Myeloma Forum, Japan
- Nobuhiko Uoshima
- Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Japan; Kansai Myeloma Forum, Japan
- Ryosuke Yamamura
- Department of Hematology, Osaka Saiseikai Nakatsu Hospital, Japan; Kansai Myeloma Forum, Japan
- Satoshi Yoshioka
- Department of Hematology, Japanese Red Cross Osaka Hospital, Japan; Kansai Myeloma Forum, Japan
- Kazunori Imada
- Department of Hematology, Japanese Red Cross Osaka Hospital, Japan; Kansai Myeloma Forum, Japan
- Yuji Shimura
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan; Kansai Myeloma Forum, Japan
- Masaaki Hotta
- First Department of Internal Medicine, Kansai Medical University, Japan; Kansai Myeloma Forum, Japan
- Toshimitsu Matsui
- Department of Hematology, Nishiwaki Municipal Hospital, Japan; Kansai Myeloma Forum, Japan
- Satoru Kosugi
- Department of Hematology, Toyonaka Municipal Hospital, Japan; Kansai Myeloma Forum, Japan
- Hitoshi Hanamoto
- Department of Hematology, Kindai University Nara Hospital, Japan; Kansai Myeloma Forum, Japan
- Hitoji Uchiyama
- Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Japan; Kansai Myeloma Forum, Japan
- Satoshi Yoshihara
- Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Japan; Kansai Myeloma Forum, Japan
- Shin-ichi Fuchida
- Department of Hematology, Japan Community Healthcare Organization Kyoto Kuramaguchi Medical Center, Japan; Kansai Myeloma Forum, Japan
- Yoshiyuki Onda
- Department of Hematology, Japanese Red Cross Takatsuki Hospital, Japan; Kansai Myeloma Forum, Japan
- Yasuhiro Tanaka
- Department of Hematology, Japanese Red Cross Wakayama Medical Center, Japan; Kansai Myeloma Forum, Japan
- Kensuke Ohta
- Hematology Ohta Clinic, Shinsaibashi, Japan; Kansai Myeloma Forum, Japan
- Mitsuhiro Matsuda
- Department of Hematology, PL General Hospital, Japan; Kansai Myeloma Forum, Japan
- Junya Kanda
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University; Kansai Myeloma Forum, Japan
- Adachi Yoko
- Department of Internal Medicine, Japan Community Healthcare Organization Kobe Central Hospital, Japan; Kansai Myeloma Forum, Japan
- Miki Kiyota
- Department of Hematology, Matsushita Memorial Hospital, Japan; Kansai Myeloma Forum, Japan
- Eri Kawata
- Department of Hematology, Matsushita Memorial Hospital, Japan; Kansai Myeloma Forum, Japan
- Ryoichi Takahashi
- Department of Hematology, Omihachiman Community Medical Center, Japan; Kansai Myeloma Forum, Japan
- Kentaro Fukushima
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan; Kansai Myeloma Forum, Japan
- Hirokazu Tanaka
- Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Japan; Kansai Myeloma Forum, Japan
- Hideo Yagi
- Department of Hematology and Oncology, Nara Prefecture General Medical Center, Japan; Kansai Myeloma Forum, Japan
- Teruhito Takakuwa
- Hematology, Graduate School of Medicine, Osaka Metropolitan University, Japan; Kansai Myeloma Forum, Japan
- Naoki Hosen
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan; Kansai Myeloma Forum, Japan
- Tomoki Ito
- First Department of Internal Medicine, Kansai Medical University, Japan; Kansai Myeloma Forum, Japan
- Chihiro Shimazaki
- Department of Hematology, Japan Community Healthcare Organization Kyoto Kuramaguchi Medical Center, Japan; Kansai Myeloma Forum, Japan
- Akifumi Takaori-Kondo
- Department of Hematology, Nishiwaki Municipal Hospital, Japan; Kansai Myeloma Forum, Japan
- Junya Kuroda
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan; Kansai Myeloma Forum, Japan
- Itaru Matsumura
- Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Japan; Kansai Myeloma Forum, Japan
- Masayuki Hino
- Hematology, Graduate School of Medicine, Osaka Metropolitan University, Japan; Kansai Myeloma Forum, Japan
- Journal volume & issue
-
Vol. 20
p. 100395
Abstract
To evaluate the specific prognostic value of CAs, we conducted an analysis of 923 symptomatic multiple myeloma patients. Among this cohort, 480 patients had complete data set of high-risk CAs by interphase fluorescent in situ hybridization at diagnosis. In the high-risk group analysis, the median OS of patients without CAs (n = 338, 72 %) was 6.5 years, patients with del(17p) (n = 42, 9 %) was 4.4 years, patients with t(4;14) or t(14;16) (n = 72, 15 %) was 4.4 years, and patients with double-positive CAs(del(17p) and t(4;14) or t(14;16)) (n = 18, 4 %) was 2.1 years (p = 0.032). Patients with double-positive CAs had a significantly worse prognosis.
